论文部分内容阅读
目的:观察美沙拉嗪与糖皮质激素联合治疗溃疡性结肠炎的临床疗效。方法:选取在2008年1月1日-2015年1月1日我医院门诊及住院部收治的溃疡性结肠炎患者40例,随机分为治疗组和对照组各20例。对照组予美沙拉嗪口服;治疗组美沙拉嗪与糖皮质激素联合治疗。第8周时观察并对比两组的临床治疗效果及不良反应的发生情况。结果:治疗组不良反应发生率为10%,显著低于对照组的25%(P<0.05)。治疗组总有效率为90.0%明显高于对照组的60.0%;差异均有统计学意义(P<0.05)。结论:美沙拉嗪与糖皮质激素联合治疗溃疡性结肠炎有较好疗效,值得临床进一步应用。
Objective: To observe the clinical efficacy of mesalazine and glucocorticoid in the treatment of ulcerative colitis. Methods: Forty patients with ulcerative colitis admitted to our hospital from January 1, 2008 to January 1, 2015 were randomly divided into treatment group (n = 20) and control group (n = 20). The control group was given mesalazine orally; the treatment group was treated with mesalazine and glucocorticoid. At week 8, the clinical effects and adverse reactions of the two groups were observed and compared. Results: The incidence of adverse reactions in the treatment group was 10%, which was significantly lower than that in the control group (P <0.05). The total effective rate was 90.0% in the treatment group was significantly higher than 60.0% in the control group; the differences were statistically significant (P <0.05). Conclusion: Mesalazine combined with glucocorticoids in the treatment of ulcerative colitis has a good curative effect and is worth further clinical application.